Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN® Nasal Spray Patents
“We are pleased with these new patent issuances and subsequent Orange Book listings. We now have four Orange Book-listed patents for NARCAN Nasal Spray,” said
Patent 9,480,644 claims nasal spray formulations, devices, and methods of treatment covering the two-milligram dose of NARCAN, which was approved in
Patent, 9,561,177 claims nasal spray formulations and methods of treatment and covering the four-milligram dose of NARCAN® Nasal Spray. The patent provides for formulations with particular spray plume characteristics and geometry, and for methods of treating opioid overdose or narcotic-induced respiratory depression with the four-milligram formulation of NARCAN.
An Orange Book listing requires an Abbreviated New Drug Application (ANDA) applicant seeking
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Corporate Contact: Investor.email@example.com Media:
Susan FormanDGI firstname.lastname@example.org 212-825-3210 Investors: Glenn GarmontSenior Vice President Argot Partnersglenn@argotpartners.com 212-600-1902